Jason Karlawish
speaker
1,378 appearances
5 recordings
1 series
first heard Feb 2021
last heard Dec 2023
Jason Karlawish’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Yeah, I would just I you know, at some point you're getting into issues of multiple comparisons.
Also, biological plausibility.
I mean, can someone limb up some b some scientific explanation for why Europeans aren't responding?
I you know, I the answer is
Eat, I think it's like s we could have done uh uh uh uh astral signs and shown that, you know, Sagittariuses don't respond as a drug.
I mean, I think we have to be very careful.
Yeah.
I mean I I I I I I I th Ken's points are well taken.
I think
Jerry Churchins need to get on board with this drug because this is the beginning, not the end of understanding
What
happens to a human's brain when you reduce amyloid.
And my hunch is five years from now, we're gonna be back on this podcast talking about the various subtypes of Alzheimer's disease that do and don't respond to the various drugs based on a variety of factors.
And you know what?
That's been the story in a variety of complex chronic diseases, especially associated with aging.
But you know, the effect in this trial, I believe, is a real effect because it is not a statistical artifact.
I think it crosses thresholds such that it's effective, it's got risks.
That's the kind of drug that should be can be in clinical practice.
I'd like to see my colleagues in our field because I think geriatricians are the kind of doctors to diagnose and treat people with these diseases.
And I hope that our field recognizes that this biomarker transformation of the disease.
Showing 741–760 of 1,378 · page 38 of 69
← Previous
Next →